3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
63
CNS
42
Genitourinary
29
Gastrointestinal
24
Lymphoid
9
Other solid neoplasm
7
Dermatologic
5
Other hematologic neoplasm
3
Endocrine
3
Plasma cell
2
Myeloid
2
Gynecologic
2
NET
1
Head & Neck
1
Breast
1
Conditions
Neuroendocrine Tumors
60
Neoplasms
7
Gastro-enteropancreatic neuroendocrine tumor
7
Carcinoid Tumor
6
Breast Neoplasms
6
Pheochromocytoma
5
Colorectal Neoplasms
5
Carcinoma, Renal Cell
5
Adenoma, Islet Cell
5
Urinary Bladder Neoplasms
4
Thyroid Neoplasms
4
Paraganglioma
4
Neoplasm Metastasis
4
Lung Neoplasms
4
Carcinoma, Neuroendocrine
4
Carcinoma, Hepatocellular
4
Brain Neoplasms
4
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Melanoma
3
Carcinoma, Medullary
3
Adrenocortical Carcinoma
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Testicular Neoplasms
2
Sarcoma
2
Neuroectodermal Tumors, Primitive
2
Lymphoma
2
Liver Neoplasms
2
Interventions
amino-acid, glucose, and electrolyte solution
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Rhabdomyosarcoma
×
NET
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled